Yumanity Therapeutics Inc - ESG Rating & Company Profile powered by AI
If you are employed by Yumanity Therapeutics Inc and you wish to licence your Sustainability rating, please contact us. Alternative corporations in the scoring industry group for Yumanity Therapeutics Inc are displayedin the table. The ESG rating for Yumanity Therapeutics Inc indicates its reporting of the UN SDGs.
Yumanity Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 0.0; made up of an environmental score of 0.0, social score of 0.0 and governance score of 0.0.
0.0
Low ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1967 | Hospira Inc | 0.3 | Low |
1967 | PRA Health Sciences Inc | 0.3 | Low |
1970 | Yumanity Therapeutics Inc | 0.0 | Low |
1970 | CSPC Innovation Pharmaceutical Co Ltd | 0.0 | Low |
1970 | CTC Bio Inc | 0.0 | Low |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Yumanity Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Does Yumanity Therapeutics Inc disclose current and historical energy intensity?
Does Yumanity Therapeutics Inc report the average age of the workforce?
Does Yumanity Therapeutics Inc reference operational or capital allocation in relation to climate change?
Does Yumanity Therapeutics Inc disclose its ethnicity pay gap?
Does Yumanity Therapeutics Inc disclose cybersecurity risks?
Does Yumanity Therapeutics Inc offer flexible work?
Does Yumanity Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Yumanity Therapeutics Inc disclose the number of employees in R&D functions?
Does Yumanity Therapeutics Inc conduct supply chain audits?
Does Yumanity Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Yumanity Therapeutics Inc conduct 360 degree staff reviews?
Does Yumanity Therapeutics Inc disclose the individual responsible for D&I?
Does Yumanity Therapeutics Inc disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Yumanity Therapeutics Inc disclose current and / or historical scope 2 emissions?
Does Yumanity Therapeutics Inc disclose water use targets?
Does Yumanity Therapeutics Inc have careers partnerships with academic institutions?
Did Yumanity Therapeutics Inc have a product recall in the last two years?
Does Yumanity Therapeutics Inc disclose incidents of discrimination?
Does Yumanity Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Has Yumanity Therapeutics Inc issued a profit warning in the past 24 months?
Does Yumanity Therapeutics Inc disclose parental leave metrics?
Does Yumanity Therapeutics Inc disclose climate scenario or pathway analysis?
Does Yumanity Therapeutics Inc disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Yumanity Therapeutics Inc disclose the pay ratio of women to men?
Does Yumanity Therapeutics Inc support suppliers with sustainability related research and development?
Does Yumanity Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Yumanity Therapeutics Inc reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Yumanity Therapeutics Inc involved in embryonic stem cell research?
Does Yumanity Therapeutics Inc disclose GHG and Air Emissions intensity?
Does Yumanity Therapeutics Inc disclose its waste policy?
Does Yumanity Therapeutics Inc report according to TCFD requirements?
Does Yumanity Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Yumanity Therapeutics Inc disclose energy use targets?
Does Yumanity Therapeutics Inc disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Yumanity Therapeutics Inc have a policy relating to cyber security?
Have a different question?
Potential Risks for Yumanity Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. The company focuses on discovering disease-modifying therapies to treat neurodegenerative diseases, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration. Its lead program is YTX-7739, a novel small molecule that is in Phase I clinical trial for the treatment of Parkinson's disease and related disorders of a-synuclein. The company is also developing YTX-9184, which is in preclinical studies to treat neurological disorders. Yumanity Therapeutics Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. The company was founded in 2014 and is headquartered in Boston, Massachusetts.